OnQuality recently announced positive news for its lead candidate OQL011, an ointment designed to treat Hand-Foot Skin Reaction (HFSR) by locally activating VEGF downstream signaling pathways. OnQuality reported positive topline data from part 1 of its Phase II NOVA-II trial (NCT04088318) showing that OQL011 met the study’s primary endpoint by meeting the company’s expectations of safety, efficacy and reduced patient-reported HFSR-related pain—down to grade 0 or 1 as per NCI CTCAE v5.0 grading of palmar-plantar erythrodysesthesia (PPE . . .

Supportive Care: OnQuality Treats Cancer’s Side Effects
Shanghai-based drug developer expands in the U.S. and Australia, focusing on conditions wrought by oncology therapies
Developing therapies that treat cancer therapy-related side effects at their molecular source is the focus of OnQuality Pharmaceuticals, a Shanghai- based drug developer with a U.S. headquarters in Seattle. OnQuality recently announced positive news for its lead candidate OQL011, an ointment designed to treat Hand-Foot Skin Reaction (HFSR) by locally activating VEGF downstream signaling pathways. [Source: FatCamera/Getty Images]